Galecto, Inc.

Equities

GLTO

US36322Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.7048 ^USD	+5.37%		+3.42%	-2.11%

Mar. 08	Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	MT

Galecto, Inc. Announces Executive Changes, Effective October 1, 2023

September 26, 2023 at 04:05 pm EDT

Galecto, Inc. announced that Bertil Lindmark, M.D., the Company?s Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company?s Chief Executive Officer. Effective October 1, 2023.

Latest news about Galecto, Inc.

Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Galecto Shares Climb After Bone Marrow Disease Treatment Trial Yields Positive Results	Dec. 21	MT
Galecto, Inc. Announces Positive Topline Results from A Phase 2A Trial of GB2064 for the Treatment of Myelofibrosis	Dec. 21	CI
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Galecto, Inc. Presents Updated Clinical Data At ESMO Congress 2023 and Provides Update on Phase 1B/2A Gallant-1 Trial	23-10-23	CI
HC Wainwright Downgrades Galecto to Neutral From Buy	23-09-28	MT
Galecto Announces Plans to Explore Strategic Alternatives	23-09-26	CI
Galecto to Explore Strategic Options, to Reduce Workforce	23-09-26	MT
Galecto, Inc. Announces Executive Changes, Effective October 1, 2023	23-09-26	CI
Galecto, Inc. Proposes to Reduce Its Workforce by 29 People, or Approximately 70% of the Existing Headcount	23-09-26	CI
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	23-08-21	MT
Sector Update: Health Care Stocks Declining in Late Afternoon Trading	23-08-15	MT
Sector Update: Health Care Stocks Easing Tuesday Afternoon	23-08-15	MT
Top Midday Decliners	23-08-15	MT
Galecto to End Lung Disease Drug Development After Trial Failed to Meet Primary Endpoint; Shares Fall	23-08-15	MT
Galecto to discontinue development of lung disease treatment	23-08-15	RE
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis	23-08-15	CI
Galecto, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-31	CI
Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	23-06-20	MT
Galecto Completes Patient Dosing in Mid-Stage Trial of Lung Disease Drug Candidate	23-05-23	MT
Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	23-03-17	MT
Galecto, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Earnings Flash (GLTO) GALECTO Posts Q3 Loss $-0.54	22-11-08	MT
Galecto, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI

Chart Galecto, Inc.

Duration

Period

More charts

Company Profile

Galecto, Inc. is a clinical-stage biotechnology company. The Company is focused on developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The Companyâs initial focus is on the development of small molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). It is developing GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Companyâs product candidate also includes GB1211, a selective oral small molecule inhibitor of galectin-three, is chemically distinct from GB0139 and is being developed for the treatment of various oncology indications and liver cirrhosis, and GB2064 is a selective oral small molecule inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which progressive fibrosis reduces the ability to form blood cells in the bone marrow.

Sector

Biotechnology & Medical Research

Calendar

2024-07-30 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7048 USD

Average target price

6 USD

Spread / Average Target

+751.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GALECTO, INC.	-2.11%	19.11M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs